Evidence map›Paper›PMID 37554763›Full record

ArticleFrontiers in endocrinology2023

Self-assembled GLP-1/glucagon peptide nanofibrils prolong inhibition of food intake.

Myriam M Ouberai, Ana L Gomes Dos Santos, Sonja Kinna, David C Hornigold, David Baker, Jacqueline Naylor, Lihuan Liang, Dominic J Corkill, Mark E Welland

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Myriam M OuberaiNanoscience Centre, Department of Engineering, University of Cambridge, Cambridge, United Kingdom.
Ana L Gomes Dos SantosAdvanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
Sonja KinnaNanoscience Centre, Department of Engineering, University of Cambridge, Cambridge, United Kingdom.
David C HornigoldCardiovascular, Renal and Metabolic Diseases, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
David BakerCardiovascular, Renal and Metabolic Diseases, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
Jacqueline NaylorCardiovascular, Renal and Metabolic Diseases, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Lihuan LiangCardiovascular, Renal and Metabolic Diseases, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
Dominic J CorkillBioscience In Vivo, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals, R&D, AstraZeneca, Cambridge, United Kingdom.
Mark E WellandNanoscience Centre, Department of Engineering, University of Cambridge, Cambridge, United Kingdom.
AstraZeneca (United Kingdom) · GBUniversity of Cambridge · GBAstraZeneca (Sweden) · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Oxyntomodulin (Oxm) hormone peptide has a number of beneficial effects on nutrition and metabolism including increased energy expenditure and reduced body weight gain. Despite its many advantages as a potential therapeutic agent, Oxm is subjected to rapid renal clearance and protease degradation limiting its clinical application. Previously, we have shown that subcutaneous administration of a fibrillar Oxm formulation can significantly prolong its bioactivity Methods: We used a protease resistant analogue of Oxm, Aib2-Oxm, to form nanfibrils depot and improve serum stability of released peptide. The nanofibrils and monomeric peptide in solution were characterized by spectroscopic, microscopic techniques, potency assay, QCM-D and Results: We show that in comparison to Oxm, Aib2-Oxm fibrils display a slower elongation rate requiring higher ionic strength solutions, and a higher propensity to dissociate. Upon subcutaneous administration of fibrillar Aib2-Oxm in rodents, a 5-fold increase in bioactivity relative to fibrillar Oxm and a significantly longer bioactivity than free Aib2-Oxm were characterized. Importantly, a decrease in food intake was observed up to 72-hour post-administration, which was not seen for free Aib2-Oxm. Conclusion: Our findings provides compelling evidence for the development of long-lasting peptide fibrillar formulations that yield extended plasma exposure and enhanced

Indexed as

GlucagonGlucagon-Like Peptide 1AnimalsEatingOxyntomodulinPeptide HydrolasesPeptidesReceptors, GlucagonGlucagonGlucagon-Like Peptide 1OxyntomodulinPeptide HydrolasesPeptidesReceptors, Glucagondepot formulationsGLP-1/glucagonmetabolic diseasesnanofibrilspeptidesself-assembly

Identifiers

PMID37554763
PMCPMC10406450
OpenAlexW4385197650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.